09/22/2023 CS321629-AV 1

Updated (2023–2024 Formula)

COVID-19 Vaccine

Interim 2023-2024 COVID-19 Immunization Schedule 

for Persons 6 Months of Age and Older 

The following tables provide COVID-19 vaccination schedules based on age, health status, and product. For detailed 

guidance see Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC. 

Table 1a. For people who are NOT moderately or severely immunocompromised*

2023-24 Moderna COVID-19 Vaccine

Vaccine type: mRNA - Do NOT use any previously available Moderna COVID-19 vaccine products.

Age COVID-19 Vaccination History†

(regardless of COVID-19 vaccine formula) 2023-24 Vaccine Schedule Administer

6 months 

through 

4 years

Unvaccinated (0 doses)

Give a 2-dose initial series. Administer:

• Dose 1 now

• Dose 2 at least 4–8 weeks after Dose 1‡ 0.25 mL/25 μg 

From single-dose vial with dark 

blue cap and green label

Intramuscular (IM) injection

1 previous dose of any Moderna COVID-19 

Vaccine (Dose 1)§

Give Dose 2 at least 4–8 weeks after the last 

dose‡

2 or more doses Moderna COVID-19 

Vaccine, NOT including at least 1 dose of 

2023–24 vaccine§¶

Give 1 dose at least 8 weeks (2 months) after 

the last dose

2 or more doses Moderna COVID-19 

Vaccine, INCLUDING at least 1 dose of 

2023–24) vaccine§¶

No further doses are indicated

5 through 

11 years

Unvaccinated (0 doses) Give 1 dose now

0.25 mL/25 μg

From single-dose vial with dark 

blue cap and green label

Intramuscular (IM) injection

Any number of previous doses COVID-19 

vaccine, NOT including at least 1 dose of 

2023–24 vaccine

Give 1 dose at least 8 weeks (2 months) after 

the last dose

Any number of previous doses COVID-19 

vaccine, INCLUDING at least 1 dose of 

2023–24 vaccine

No further doses are indicated

12 years 

and older 

Unvaccinated (0 doses) Give 1 dose now 0.5 mL/50 μg

From single-dose vial with dark 

blue cap and blue label

Intramuscular (IM) injection

Any number of previous doses COVID-19 

vaccine, NOT including at least 1 dose of 

2023–24 vaccine

Give 1 dose at least 8 weeks (2 months) after 

the previous dose

Any number of previous doses COVID-19 

vaccine, INCLUDING at least 1 dose of 

2023–24 vaccine

No further doses are indicated

* Persons with a recent SARS-CoV-2 infection may consider delaying vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic).

† COVID-19 vaccination history refers to previous receipt of dose(s) of original monovalent (ancestral) mRNA, bivalent mRNA vaccine, Updated (2023–2024 Formula), or a combination of 

the three, unless otherwise specified.

‡ An 8-week interval between the first and second COVID-19 vaccine (Moderna, Novavax, and Pfizer-BioNTech) doses might be optimal for some people as it might reduce the small risk 

of myocarditis and pericarditis associated with these vaccines.

§ People who are recommended to receive a multidose mRNA series for initial vaccination (i.e., children ages 6 months–4 years and people who are moderately or severely 

immunocompromised) should receive all doses from the same manufacturer. However, in the following exceptional situations a different age-appropriate COVID-19 vaccine product 

may be administered: the same vaccine is not available, the person would otherwise not complete the vaccination series, or the person starts but is unable to complete a vaccination 

series with the same vaccine due to a contraindication.

¶ For children who have received 1 Moderna and 1 Pfizer-BioNTech vaccines of any formulation, follow a 3-dose schedule. A third dose of either Moderna vaccine or Pfizer-BioNTech 

vaccine should be administered at least 8 weeks after the second dose.
09/22/2023 CS321629-AV 2

Updated (2023–2024 Formula)

COVID-19 Vaccine

Interim 2023-2024 COVID-19 Immunization Schedule 

for Persons 6 Months of Age and Older 

Table 1b. For people who are NOT moderately or severely immunocompromised*

2023-24 Pfizer-BioNTech COVID-19 Vaccine

Vaccine type: mRNA - Do NOT use any previously available Pfizer-BioNTech COVID-19 vaccine products.

Age COVID-19 Vaccination History†

(regardless of COVID-19 vaccine formula) 2023-24 Vaccine Schedule Administer

6 months 

through 

4 years

Unvaccinated (0 doses)

Give a 3-dose initial series. Administer:

• Dose 1 now

• Dose 2 at least 3-8 weeks after Dose 1‡

• Dose 3 at least 8 weeks (2 months) after Dose 2

0.3 mL/3 μg

From yellow-capped vial 

with yellow label

Intramuscular (IM) injection

1 previous dose of any Pfizer-BioNTech 

COVID-19 Vaccine (Dose 1)§

Complete series. Administer:

• Dose 2 at least 3–8 weeks after Dose 1‡

• Dose 3 at least 8 weeks (2 months) after Dose 2

2 doses of any Pfizer-BioNTech COVID-19 

Vaccine (Doses 1 and 2)§¶

Complete series. Administer:

• Dose 3 at least 8 weeks (2 months) after Dose 2

3 or more doses Pfizer-BioNTech COVID-19 

Vaccine, NOT including at least 1 dose of 

2023–24 COVID-19 vaccine§

Give 1 dose at least 8 weeks (2 months) after the last 

dose

3 or more doses Pfizer-BioNTech COVID-19 

Vaccine, INCLUDING at least 1 dose of 

2023–24 COVID-19 vaccine§

No further doses are indicated

5 through 

11 years

Unvaccinated (0 doses) Give 1 dose now 0.3 mL/10 μg

From blue-capped vial with 

blue label

Intramuscular (IM) injection

Any number of previous doses COVID-19 

vaccine, NOT including at least 1 dose of 

2023–24 COVID-19 vaccine

Give 1 dose at least 8 weeks (2 months) after the last 

dose

Any number of previous doses COVID-19 

vaccine, INCLUDING at least 1 dose of 

2023–24 COVID-19 vaccine

No further doses are indicated

12 years 

and older 

Unvaccinated (0 doses) Give 1 dose now 0.3 mL/30 μg

From gray-capped vial with 

gray label or manufacturerfilled syringe with gray box 

on label

Intramuscular (IM) injection

Any number of previous doses COVID-19 

vaccine, NOT including at least 1 dose of 

2023–24 COVID-19 vaccine

Give 1 dose at least 8 weeks (2 months) after the last 

dose

Any number of previous doses COVID-19 

vaccine, INCLUDING at least 1 dose of 

2023–24 COVID-19 vaccine

No further doses are indicated

* Persons with a recent SARS-CoV-2 infection may consider delaying vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic).

† COVID-19 vaccination history refers to previous receipt of dose(s) of original monovalent (ancestral) mRNA, bivalent mRNA vaccine, Updated (2023–2024 Formula), or a combination of 

the three, unless otherwise specified.

‡ An 8-week interval between the first and second COVID-19 vaccine (Moderna, Novavax, and Pfizer-BioNTech) doses might be optimal for some people as it might reduce the small risk 

of myocarditis and pericarditis associated with these vaccines.

§ People who are recommended to receive a multidose mRNA series for initial vaccination (i.e., children ages 6 months–4 years and people who are moderately or severely 

immunocompromised) should receive all doses from the same manufacturer. However, in the following exceptional situations a different age-appropriate COVID-19 vaccine product 

may be administered: the same vaccine is not available, the person would otherwise not complete the vaccination series, or the person starts but is unable to complete a vaccination 

series with the same vaccine due to a contraindication.

¶ For children who have received 1 Moderna and 1 Pfizer-BioNTech vaccines of any formulation, follow a 3-dose schedule. A third dose of either Moderna vaccine or Pfizer-BioNTech 

vaccine should be administered at least 8 weeks after the second dose.
09/22/2023 CS321629-AV 3

Updated (2023–2024 Formula)

COVID-19 Vaccine

Interim 2023-2024 COVID-19 Immunization Schedule 

for Persons 6 Months of Age and Older 

Table 2a. For people who ARE moderately or severely immunocompromised

2023-24 Moderna COVID-19 Vaccine

Vaccine type: mRNA - Do NOT use any previously available Moderna COVID-19 vaccine products.

Age COVID-19 Vaccination History*

(regardless of COVID-19 vaccine formula) 2023-24 Vaccine Schedule Administer

6 months 

through 

4 years

Unvaccinated (0 doses)

Give a 3-dose initial series. Administer:

• Dose 1 now

• Dose 2 at least 4 weeks after Dose 1

• Dose 3 at least 4 weeks after Dose 2

0.25 mL/25 μg 

From single-dose vial 

with dark blue cap 

and green label

Intramuscular (IM) 

injection

1 previous dose of any Moderna COVID-19 

Vaccine (Dose 1)†

Complete series. Administer:

• Dose 2 at least 4 weeks after Dose 1

• Dose 3 at least 4 weeks after Dose 2

2 doses of any Moderna COVID-19 Vaccine 

(Doses 1 and 2)†‡

Complete series. Administer:

• Dose 3 at least 4 weeks after Dose 2

3 or more doses of Moderna COVID-19 

Vaccine, NOT including at least 1 dose of 

2023–24 COVID-19 vaccine†

Give 1 dose at least 8 weeks (2 months) after the previous dose

3 or more doses of Moderna COVID-19 

Vaccine, INCLUDING at least 1 dose of 

2023–24 COVID-19 vaccine†

People who are moderately or severely immunocompromised 

have the option to receive 1 additional dose at least 8 

weeks (2 months) following the last recommended dose. 

Further additional dose(s) may be administered, informed by 

the clinical judgement of a healthcare provider and personal 

preference and circumstances. 

Any further additional doses should be administered at least 8 

weeks (2 months) after the last COVID-19 vaccine dose.

5 through 

11 years

Unvaccinated (0 doses)

Give a 3-dose initial series. Administer:

• Dose 1 now

• Dose 2 at least 4 weeks after Dose 1

• Dose 3 at least 4 weeks after Dose 2

0.25 mL/25 μg

From single-dose vial 

with dark blue cap 

and green label

Intramuscular (IM) 

injection

1 previous dose of any Moderna COVID-19 

Vaccine (Dose 1)†

Complete series. Administer:

• Dose 2 at least 4 weeks after Dose 1

• Dose 3 at least 4 weeks after Dose 2

2 doses of any Moderna COVID-19 Vaccine 

(Doses 1 and 2)†

Complete series. Administer:

• Dose 3 at least 4 weeks after Dose 2

3 or more doses of Moderna COVID-19 

Vaccine, NOT including at least 1 dose of 

2023–24 COVID-19 vaccine†

Give 1 dose at least 8 weeks (2 months) after the last dose

3 or more doses of Moderna COVID-19 

Vaccine, INCLUDING at least 1 dose of 

2023–24 COVID-19 vaccine†

People who are moderately or severely immunocompromised 

have the option to receive 1 additional dose at least 8 

weeks (2 months) following the last recommended dose. 

Further additional dose(s) may be administered, informed by 

the clinical judgement of a healthcare provider and personal 

preference and circumstances. 

Any further additional doses should be administered at least 8 

weeks (2 months) after the last COVID-19 vaccine dose.

* COVID-19 vaccination history refers to previous receipt of dose(s) of original monovalent (ancestral) mRNA, bivalent mRNA vaccine, Updated (2023–2024 Formula), or a combination of 

the three, unless otherwise specified.

† People who are recommended to receive a multidose mRNA series for initial vaccination (i.e., children ages 6 months–4 years and people who are moderately or severely 

immunocompromised) should receive all doses from the same manufacturer. However, in the following exceptional situations a different age-appropriate COVID-19 vaccine product 

may be administered: the same vaccine is not available, the person would otherwise not complete the vaccination series, or the person starts but is unable to complete a vaccination 

series with the same vaccine due to a contraindication.

‡ For children who have received 1 Moderna and 1 Pfizer-BioNTech vaccines of any formulation, follow a 3-dose schedule. A third dose of either Moderna vaccine or Pfizer-BioNTech 

vaccine should be administered at least 8 weeks after the second dose. 
09/22/2023 CS321629-AV 4

Updated (2023–2024 Formula)

COVID-19 Vaccine

Interim 2023-2024 COVID-19 Immunization Schedule 

for Persons 6 Months of Age and Older 

Table 2a. For people who ARE moderately or severely immunocompromised Continued

2023-24 Moderna COVID-19 Vaccine - CONTINUED

Vaccine type: mRNA - Do NOT use any previously available Moderna COVID-19 vaccine products.

Age COVID-19 Vaccination History*

(regardless of COVID-19 vaccine formula) 2023-24 Vaccine Schedule Administer

12 years 

and older 

Unvaccinated 0 doses

Give a 3-dose initial series. Administer:

• Dose 1 now

• Dose 2 at least 4 weeks after Dose 1

• Dose 3 at least 4 weeks after Dose 2

0.5 mL/50 μg

From single-dose vial 

with dark blue cap 

and blue label

Intramuscular (IM) 

injection

1 previous dose of any Moderna COVID-19 

Vaccine (Dose 1)†

Complete series. Administer:

• Dose 2 at least 4 weeks after Dose 1

• Dose 3 at least 4 weeks after Dose 2

2 doses of any Moderna COVID-19 Vaccine 

(Doses 1 and 2)†

Complete series. Administer:

• Dose 3 at least 4 weeks after Dose 2

3 or more doses of Moderna COVID-19 

Vaccine, NOT including at least 1 dose of 

2023–24 COVID-19 vaccine†

Give 1 dose at least 8 weeks (2 months) after the previous dose

3 or more doses of Moderna COVID-19 

Vaccine, INCLUDING at least 1 dose of 

2023–24 COVID-19 vaccine†

People who are moderately or severely immunocompromised 

have the option to receive 1 additional dose at least 8 

weeks (2 months) following the last recommended dose. 

Further additional dose(s) may be administered, informed by 

the clinical judgement of a healthcare provider and personal 

preference and circumstances. 

Any further additional doses should be administered at least 8 

weeks (2 months) after the last COVID-19 vaccine dose.

* COVID-19 vaccination history refers to previous receipt of dose(s) of original monovalent (ancestral) mRNA, bivalent mRNA vaccine, Updated (2023–2024 Formula), or a combination of 

the three, unless otherwise specified.

† People who are recommended to receive a multidose mRNA series for initial vaccination (i.e., children ages 6 months–4 years and people who are moderately or severely 

immunocompromised) should receive all doses from the same manufacturer. However, in the following exceptional situations a different age-appropriate COVID-19 vaccine product 

may be administered: the same vaccine is not available, the person would otherwise not complete the vaccination series, or the person starts but is unable to complete a vaccination 

series with the same vaccine due to a contraindication.
09/22/2023 CS321629-AV 5

Updated (2023–2024 Formula)

COVID-19 Vaccine

Interim 2023-2024 COVID-19 Immunization Schedule 

for Persons 6 Months of Age and Older 

Table 2b. For people who ARE moderately or severely immunocompromised

2023-24 Pfizer-BioNTech COVID-19 Vaccine

Vaccine type: mRNA - Do NOT use any previously available Pfizer-BioNTech COVID-19 vaccine products.

Age COVID-19 Vaccination History*

(regardless of COVID-19 vaccine formula) 2023-24 Vaccine Schedule Administer

6 months 

through 

4 years

Unvaccinated: (0 doses)

Give a 3-dose initial series. Administer:

• Dose 1 now

• Dose 2 at least 3 weeks after Dose 1

• Dose 3 at least 8 weeks (2 months) after Dose 2

0.3 mL/3 μg 

From yellow-capped 

vial with yellow label

Intramuscular (IM) 

injection

1 previous dose of any Pfizer-BioNTech 

COVID-19 Vaccine (Dose 1)†

Complete series. Administer:

• Dose 2 at least 3 weeks after Dose 1

• Dose 3 at least 8 weeks (2 months) after Dose 2

2 doses of any Pfizer-BioNTech COVID-19 

Vaccine (Doses 1 and 2)†‡

Complete series. Administer:

• Dose 3 at least 8 weeks (2 months) after Dose 2

3 or more doses of Pfizer-BioNTech 

COVID-19 Vaccine, NOT including at least 1 

dose of 2023–24 COVID-19 vaccine †

Give 1 dose at least 8 weeks (2 months) after the previous dose

3 or more doses of Pfizer-BioNTech 

COVID-19 Vaccine, INCLUDING at least 1 

dose of 2023–24 COVID-19 vaccine†

People who are moderately or severely immunocompromised 

have the option to receive 1 additional dose at least 8 

weeks (2 months) following the last recommended dose. 

Further additional dose(s) may be administered, informed by 

the clinical judgement of a healthcare provider and personal 

preference and circumstances. 

Any further additional doses should be administered at least 8 

weeks (2 months) after the last COVID-19 vaccine dose.

5 through 

11 years

Unvaccinated: (0 doses)

Give a 3-dose initial series. Administer:

• Dose 1 now

• Dose 2 at least 3 weeks after Dose 1

• Dose 3 at least 4 weeks after Dose 2

0.3 mL/10 μg

From blue-capped 

vial with blue label

Intramuscular (IM) 

injection

1 previous dose of any Pfizer-BioNTech 

COVID-19 Vaccine (Dose 1)†

Complete series. Administer:

• Dose 2 at least 3 weeks after Dose 1

• Dose 3 at least 4 weeks after Dose 2

2 doses of any Pfizer-BioNTech COVID-19 

Vaccine (Doses 1 and 2)†

Complete series. Administer:

• Dose 3 at least 4 weeks after Dose 2

3 or more doses of Pfizer-BioNTech 

COVID-19 Vaccine, NOT including at least 1 

dose of 2023–24 COVID-19 vaccine†

Give 1 dose at least 8 weeks (2 months) after the last dose

3 or more doses of Pfizer-BioNTech 

COVID-19 Vaccine, INCLUDING at least 1 

dose of 2023–24 COVID-19 vaccine†

People who are moderately or severely immunocompromised 

have the option to receive 1 additional dose at least 8 

weeks (2 months) following the last recommended dose. 

Further additional dose(s) may be administered, informed by 

the clinical judgement of a healthcare provider and personal 

preference and circumstances. 

Any further additional doses should be administered at least 8 

weeks (2 months) after the last COVID-19 vaccine dose.

* COVID-19 vaccination history refers to previous receipt of dose(s) of original monovalent (ancestral) mRNA, bivalent mRNA vaccine, Updated (2023–2024 Formula), or a combination of 

the three, unless otherwise specified.

† People who are recommended to receive a multidose mRNA series for initial vaccination (i.e., children ages 6 months–4 years and people who are moderately or severely 

immunocompromised) should receive all doses from the same manufacturer. However, in the following exceptional situations a different age-appropriate COVID-19 vaccine product 

may be administered: the same vaccine is not available, the person would otherwise not complete the vaccination series, or the person starts but is unable to complete a vaccination 

series with the same vaccine due to a contraindication.

‡ For children who have received 1 Moderna and 1 Pfizer-BioNTech vaccines of any formulation, follow a 3-dose schedule. A third dose of either Pfizer-BioNTech vaccine or Pfizer-BioNTech 

vaccine should be administered at least 8 weeks after the second dose. 
09/22/2023 CS321629-AV 6

Updated (2023–2024 Formula)

COVID-19 Vaccine

Interim 2023-2024 COVID-19 Immunization Schedule 

for Persons 6 Months of Age and Older 

Table 2b. For people who ARE moderately or severely immunocompromised Continued

2023-24 Pfizer-BioNTech COVID-19 Vaccine - CONTINUED

Vaccine type: mRNA - Do NOT use any previously available Pfizer-BioNTech COVID-19 vaccine products.

Age COVID-19 Vaccination History*

(regardless of COVID-19 vaccine formula) 2023-24 Vaccine Schedule Administer

12 years 

and older 

Unvaccinated: 0 doses

Give a 3-dose initial series. Administer:

• Dose 1 now

• Dose 2 at least 3 weeks after Dose 1

• Dose 3 at least 4 weeks after Dose 2

0.3 mL/30 μg

From gray-capped 

vial with gray label or 

manufacturer-filled 

syringe with gray box 

on label

Intramuscular (IM) 

injection

1 previous dose of any Pfizer-BioNTech 

COVID-19 Vaccine (Dose 1)†

Complete series. Administer:

• Dose 2 at least 3 weeks after Dose 1

• Dose 3 at least 4 weeks after Dose 2

2 doses of any Pfizer-BioNTech COVID-19 

Vaccine (Doses 1 and 2)†

Complete series. Administer:

• Dose 3 at least 4 weeks after Dose 2

3 or more doses of Pfizer-BioNTech 

COVID-19 Vaccine, NOT including at least 1 

dose of 2023–24 COVID-19 vaccine †

Give 1 dose at least 8 weeks (2 months) after the last dose

3 or more doses of Pfizer-BioNTech 

COVID-19 Vaccine, INCLUDING at least 1 

dose of 2023–24 COVID-19 vaccine †

People who are moderately or severely immunocompromised 

have the option to receive 1 additional dose at least 8 

weeks (2 months) following the last recommended dose. 

Further additional dose(s) may be administered, informed by 

the clinical judgement of a healthcare provider and personal 

preference and circumstances. 

Any further additional doses should be administered at least 8 

weeks (2 months) after the last COVID-19 vaccine dose.

* COVID-19 vaccination history refers to previous receipt of dose(s) of original monovalent (ancestral) mRNA, bivalent mRNA vaccine, Updated (2023–2024 Formula), or a combination of 

the three, unless otherwise specified.

† People who are recommended to receive a multidose mRNA series for initial vaccination (i.e., children ages 6 months–4 years and people who are moderately or severely 

immunocompromised) should receive all doses from the same manufacturer. However, in the following exceptional situations a different age-appropriate COVID-19 vaccine product 

may be administered: the same vaccine is not available, the person would otherwise not complete the vaccination series, or the person starts but is unable to complete a vaccination 

series with the same vaccine due to a contraindication.